Oral Minoxidil Dosing for Hair Loss
For men, start with 2.5 mg daily and advance to 5 mg daily; for women, start with 1.25 mg daily (or 0.5-0.625 mg for those with low weight, baseline low blood pressure, or cardiovascular history), with doses remaining at the starting level for several weeks before any titration. 1
Sex-Specific Starting Doses
Men
- Standard starting dose: 2.5 mg once daily
- Target dose: 5 mg daily (can be advanced after tolerating starting dose)
- Most men tolerate this progression without side effects 1
Women
Two dosing scenarios based on risk stratification:
- Standard-risk women: 1.25 mg once daily 1
- High-risk women (low body weight, baseline hypotension <90/60 mmHg, or cardiovascular history): 0.5 mg (compounded) or 0.625 mg (¼ of 2.5 mg tablet) 1
This sex-based differentiation is critical because women are more susceptible to cardiovascular effects even at doses as low as 0.25-0.5 mg daily 1.
Titration Protocol
- Remain on starting dose for at least several weeks to assess for persistent adverse effects 1
- Only advance dose after confirming no or acceptable side effects at current dose 1
- Maximum dose: 5 mg daily (defines "low-dose" oral minoxidil) 1
Critical Monitoring Requirements
Blood pressure and pulse monitoring is essential due to rapid absorption:
- Check BP and pulse before and 2 hours after the first dose (when minoxidil-induced effects peak) 1
- Peak plasma levels occur at 30-60 minutes; antihypertensive effects begin within 30-60 minutes 1
- Repeat monitoring with each dose escalation 1
- Any unwanted BP decrease may last days 1
Absolute Contraindications
Based on international Delphi consensus 2:
- Pericardial disease
- Uncontrolled hypertension
- Pregnancy or breastfeeding 1
- Hypersensitivity to minoxidil ingredients
Precautions (Require Careful Consideration)
- History of tachycardia or arrhythmia (81.8% expert consensus) 2
- Hypotension (BP <90/60 mmHg) (77.3% consensus) 2
- Renal impairment (88.4% consensus) - minoxidil is renally excreted within 12-20 hours 2
- Patients on dialysis (88.4% consensus) 2
Expected Adverse Effects and Management
Common (Dose-Dependent)
Hypertrichosis: 15-24% - typically appears by 2-4 months, most common on sideburns/temples 1, 3, 4
- Management: local hair removal, dose reduction, or antiandrogens
- Resolves within 1-6 months after stopping 1
Transient shedding: 16-22% - occurs at 4-6 weeks, indicates synchronization into new growth phase, is temporary and positive 1
Fluid retention: 1.3-2% - appears at 2-4 months 1, 4
- Management: dose reduction or diuretic
Serious (Rare but Critical)
- Tachycardia: 0.9% - can precipitate angina via increased cardiac contractility and oxygen demand 1, 4
- Pericardial effusion - rare but documented even at 0.25 mg/day 1
- Stop immediately if chest pain or shortness of breath develops and seek emergency care 1
Treatment Discontinuation Rate
Only 1.7% of patients discontinued due to adverse effects in the largest safety study of 1,404 patients 4
Key Clinical Pitfalls
- Beta-blockers interaction: May block reflex tachycardia but potentiate hypotensive effects 1
- Women are more sensitive: Some experience issues even at 0.25-0.5 mg daily 1
- Not FDA-approved for hair loss: This is off-label use based on pharmacology and clinical experience 1
- Cardiovascular effects are immediate: Unlike hypertrichosis (2-4 months) or fluid retention (2-4 months), BP/pulse changes occur within 30-60 minutes 1
Evidence Quality Note
The 2025 JAMA Dermatology international Delphi consensus 2 and 2025 Journal of the American Academy of Dermatology recommendations [1-1] represent the highest quality, most recent guidance available. These guidelines acknowledge that dosing has been "determined largely by trial and error" without randomized controlled trials 1, making the consensus-based approach particularly valuable for standardizing clinical practice.